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Abstract
Metformin is the mainstay therapy for type 2 diabetes (T2D) and many patients also take 
salicylate-based drugs [i.e., aspirin (ASA)] for cardioprotection. Metformin and salicylate both 
increase AMP-activated protein kinase (AMPK) activity but by distinct mechanisms, with 
metformin altering cellular adenylate charge (increasing AMP) and salicylate interacting directly 
at the AMPK β1 drug-binding site. AMPK activation by both drugs results in phosphorylation of 
ACC (acetyl-CoA carboxylase; P-ACC) and inhibition of acetyl-CoA carboxylase (ACC), the rate 
limiting enzyme controlling fatty acid synthesis (lipogenesis). We find doses of metformin and 
salicylate used clinically synergistically activate AMPK in vitro and in vivo, resulting in reduced 
liver lipogenesis, lower liver lipid levels and improved insulin sensitivity in mice. Synergism 
occurs in cell-free assays and is specific for the AMPK β1 subunit. These effects are also observed 
in primary human hepatocytes and patients with dysglycaemia exhibit additional improvements in 
a marker of insulin resistance (proinsulin) when treated with ASA and metformin compared with 
either drug alone. These data indicate that metformin–salicylate combination therapy may be 
efficacious for the treatment of non-alcoholic fatty liver disease (NAFLD) and T2D.
Keywords
aspirin; acetyl-CoA carboxylase; salsalate; non-alcoholic fatty liver disease; type 2 diabetes
1To whom correspondence should be addressed (gsteinberg@mcmaster.ca). 
AUTHOR CONTRIBUTIONS
Rebecca Ford, Morgan Fullerton, Stephen Pinkosky and Gregory Steinberg designed the study. Rebecca Ford, Emily Day, Morgan 
Fullerton, Stephen Pinkosky, Adam Bujak., Brennan Smith, Katarina Marcinko, Regje Blümer and Justin Crane performed 
experiments and data analyses. Hertzel Gerstein analysed human subject data and provided consultation. John Scott, Jonathan Oakhill 
and Bruce Kemp contributed the AMPK in vitro studies, Rebecca Ford, Stephen Pinkosky, Hertzel Gerstein, Bruce Kemp and Gregory 
Steinberg wrote the manuscript. All authors contributed to editing the final manuscript draft.
Biochem J. Author manuscript; available in PMC 2017 January 12.
Published in final edited form as:




















Non-alcoholic fatty liver disease (NAFLD) is estimated to affect nearly 40 %of all adults 
and more than 80 %of those with type 2 diabetes (T2D) [1]. Elevated rates of liver fatty acid 
synthesis (de novo lipogenesis) cause NAFLD in humans [2] and NAFLD may promote the 
development of T2D by reducing liver insulin sensitivity [3]. Therefore pharmacological 
strategies aimed at inhibiting liver lipogenesis may be effective to reduce or reverse the 
prevalence of NAFLD and improve insulin sensitivity.
AMP-activated protein kinase (AMPK) is an αβγ heterotrimer that inhibits a rate limiting 
step of liver fatty acid synthesis through inhibitory phosphorylation of acetyl-CoA 
carboxylase 1 and 2 [ACC1 and ACC2; P-ACC); 4,5]. Importantly, mice deficient in the 
AMPK phosphorylation sites on ACC accumulate enhanced levels of liver fat and develop 
insulin resistance [6], indicating the importance of this pathway in maintaining metabolic 
homoeostasis. Metformin and salicylate [the active metabolite of aspirin (ASA) and 
salsalate] both activate AMPK, albeit by different mechanisms: metformin increases AMPK 
activity indirectly by inhibiting mitochondrial respiration and increasing AMP levels [7], 
whereas salicylate-induced activation requires the AMPK β1 subunit [8]. Metformin-and 
salicylate-based therapeutics (ASA and salsalate) improve liver insulin sensitivity [9–11], 
effects which may involve the activation of AMPK and subsequent P-ACC [6,8].
Given that metformin and salicylate activate AMPK via distinct mechanisms, we 
hypothesized that co-treatment using these drugs would synergistically increase liver AMPK 
activity/P-ACC, reduce lipogenesis and improve insulin sensitivity. In the present study, we 
provide novel evidence that low, clinically-relevant doses of metformin and salicylate 
synergistically activate AMPK to inhibit lipogenesis in primary hepatocytes from mice and 
humans. Synergistic activation of AMPK occurs in cell-free assays and is dependent on the 
expression of the AMPK β1 isoform. Importantly, combination therapy also improves 
glucose tolerance, hepatic insulin sensitivity and reduces the accumulation of liver fat in 
high fat diet (HFD)-fed mice whereas lowering pro-insulin levels (a marker of insulin 




Male C57bl/6 mice were maintained on a 12-h light dark cycle (lights on at 7.00 am) and 
housed in a pathogen-free facility at 23 °C with bedding enrichment. At 8 weeks of age, 
mice were either killed to obtain primary hepatocytes or switched from a standard chow diet 
to a HFD [60 % kcal (1 cal ≡ 4.184 J) from fat, diet D12492 from Research Diets] for 5 
weeks. At 13 weeks of age, glucose tolerance tests (GTTs; described in detail below) were 
performed to confirm a metabolically compromised phenotype (result not shown) and 
animals were assigned to four groups matched for weight and glucose tolerance. Since we 
were specifically interested in testing the effects of the low-dose metformin and/or salsalate 
in obesity, we did not study control chow-fed mice. Importantly, the HFD-fed mice used in 
the current study had comparable levels of obesity/adiposity, glucose tolerance, insulin 
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resistance and liver triglycerides (TG) compared with those of our recent studies in which 
both chow and HFD-mice were studied [6,13]. As dictated by design, mice that were not 
obese (<32 g) after the initial 5 weeks of HFD were excluded from the study and all further 
analyses. The four groups were then randomly assigned to begin feeding of HFD containing 
no drug [control], 2.5 g/kg metformin, 1 g/kg salsalate or both 2.5 g/kg metformin and 1 
g/kg salsalate (metformin + salsalate) for an additional 5 weeks.
Study approval
All animal procedures were approved by the McMaster University Animal Ethics Research 
Board (AUP #: 12–12-44). Human results were obtained from data collected during the 
Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial (NCT00069784, 
[14]), which was approved a priori by the ethics committee at each site. Written informed 
consent was obtained from all participants prior to inclusion in the study.
Primary cell culture
Mouse primary hepatocytes were obtained from C57bl/6 mice by collagenase digestion, as 
previously described [6,15]. For human primary hepatocyte experiments, cryopreserved 
primary human hepatocytes (Triangle Research Labs) were thawed, centrifuged and re-
suspended in complete William’s E medium (11 mM glucose) containing 10 % FBS and 
plated in 24-well collagen coated plates at 0.35 × 106 cells/well and allowed to adhere for 4 
h. Donors of cryopreserved human hepatocytes were male [age 46, body mass index (BMI) 
23.5] and female (age 59, BMI 29), were non-drug users (including alcohol), non-smokers. 
All experiments were performed the following morning after hepatocytes were serum 
starved for 3- (mouse) or 18- (human) h in the William’s E medium (11 mM glucose). For 
[3H]-acetate fatty acid synthesis, cells were treated with no drug, metformin, salicylate or 
metformin + salicylate, [3H]-acetate (5 μCi/μl) and sodium acetate (0.5 mM) for 4 h in 
serum-free William’s E medium (11 mM glucose) as described [6]. Medium was then 
removed and cells were washed twice with PBS before extraction of total lipids using 
chloroform–methanol [16]. Drug synergy in fatty acid synthesis experiments was calculated 
using the Chou–Talalay method and CompuSyn software [17,18]. [14C]-palmitate fatty acid 
oxidation was performed as described previously [6], with minor modifications including 
pre-treatment of hepatocytes for 1 h with drugs followed by 4 h treatment with 200 μM 
palmitate (complexed with 2 % BSA, with radiolabel at 0.5 μCi/ml), 500 μM L-carnitine and 
drugs in serum-free media before the cells and media were collected for the assay. For 
Western blots, cells were treated with vehicle or drugs for 2 h. Medium was then removed 
and cell lysis buffer applied to cells rapidly on ice and plates snap frozen on liquid nitrogen, 
as described previously [19]. Lysates were stored at − 80 °C for further analyses.
AMPK activity assay
Heterotrimeric human AMPK GST-α1β1γ1 was expressed by transient transfection of 
COS7 cells cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 10 % FBS 
as described previously [20]. Transfected cells were harvested by washing with ice-cold PBS 
followed by rapid lysis in situ using 1 ml of lysis buffer [50 mM Tris/HCl, pH 7.4, 150 mM 
NaCl, 50 mM NaF, 1 mM NaPPi, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 % (v/v) Triton 
X-100]. Cellular debris was removed by centrifugation, after which AMPK was isolated 
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from the lysates on glutathione Sepharose 4B (GE Life Sciences), extensively washed with 
lysis buffer and then dephosphorylated with λ-phosphatase (2 mM MnCl2, 2 h, 22 °C) prior 
to elution in storage buffer 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 10 % glycerol, 2 mM 
TCEP [tris(2-carboxyethyl)phosphine], 20 mM reduced glutathione. For AMPK α1β1γ1 
and α1β2γ1 expressed in bacteria, all procedures were as described previously [20].
AMPK activity was determined by phosphorylation of the SAMS peptide 
(HMRSAMSGLHLVKRR) using 100 μM SAMS, 200 μM [γ-32P] ATP, 5 mM MgCl2 and 
indicated ligands in 25 μl of reaction volume at 30 °C. Reactions were terminated after 10 
min by spotting 15 μl on to P81 phosphocellulose paper (Whatman) and washing in 1 % 
phosphoric acid [21]. Radioactivity was quantified by scintillation counting.
Metabolic studies
GTTs and insulin tolerance tests (ITTs) were performed by intraperitoneal injection of 
glucose (0.8 g/kg body weight) or human insulin (1 unit insulin/kg body weight) 
respectively and blood glucose measured by Aviva blood glucose monitor (Roche) from a 
small tail vein nick at the time points indicated. Mice were fasted for 6 h prior to all 
tolerance tests. Respiratory exchange ratio (RER) was assessed using a Columbus 
Laboratory Animal Monitoring System [22]. Whole body adiposity was measured using 
computed tomography [22]. Fasting (12 h) and fed blood samples were collected by tail vein 
bleed for serum measurements. Commercially available ELISA kits were used to measure 
serum salicylate (Neogen) and insulin [Millipore (rodent) and Mercodia (human)]. Serum 
metformin levels were measured by MS using a PE/Sciex 3000 LC–MS/MS system after 
solvent extraction. Phenformin was used as an internal standard and metformin was eluted at 
3.5 min on the chromatograph.
Hyperinsulinaemic–euglycaemic clamps
Hyperinsulinaemic–euglycaemic clamps were performed as previously described [6]. 
Briefly, 5 days after cannulating the right jugular vein, mice were fasted for 6 h then infused 
with D-[3-3H]-glucose for 1 h for assessment of basal glucose disposal. A human insulin 
infusate containing D-[3-3H]-glucose was then applied and blood glucose monitored and 
titrated with 50 %dextrose infused at a variable rate to achieve and maintain euglycaemia. 
Basal and clamped glucose disposal rates (GDRs) and hepatic glucose production (HGP) 
rates were calculated as previously stated [6]. All tissues were rapidly dissected, snap frozen 
in liquid nitrogen and stored at − 80 °C for later analyses.
Immunoblotting, histological and biochemical analyses
Tissue or cell lysates were diluted with Western sample buffer and loaded in SDS/PAGE 
(7.5 % gels) as previously described [6]. After resolution of proteins by molecular mass, 
proteins were transferred to polyvinylidene difluoride membranes and blocked in 5 %BSA. 
All primary antibodies were obtained from Cell Signaling Technologies [P-ACC Ser79/212, 
ACC, β-actin, P-Akt/PKB (protein kinase B) Ser473, P-Akt/PKB Thr308, Akt/PKB] and used 
at concentrations of 1:1000 except β-actin which was used at 1:5000. For liver histology, all 
tissues were fixed in formalin (for at least 48 h), paraffin embedded and sectioned for 
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haematoxylin and eosin (H & E) staining. After staining, two sections from each sample 
were imaged in triplicate. Liver lipid levels were measured by glycerol assay (Sigma) [6].
Analyses and modelling of clinical population data
Linear regression analyses were performed on proinsulin levels from patients recruited into 
the ORIGIN trial [14]. All participants had some degree of glucose elevation that ranged 
from slightly elevated glucose to clinically important degrees of hyperglycaemia [i.e. median 
fasting plasma glucose (FPG) = 6.9 mmol/l and median glycated haemoglobin A1c (HbA1c) 
= 6.4%]. Associations of metformin and/or ASA with proinsulin levels were obtained after 
adjusting for age, sex, weight, FPG levels, HbA1c and insulin levels.
Statistical analyses
All values are reported as mean ± S.E.M. Data were analysed −using Student’s t tests or 
one-way ANOVA or repeated measures ANOVA with Tukey’s or Bonferroni post-hoc tests 
where appropriate. Differences were considered significant when P < 0.05.
RESULTS
Metformin and salicylate synergistically activate AMPK and inhibit lipogenesis in mouse 
primary hepatocytes
High doses of both metformin (0.5 mM) [6] and salicylate (3–5 mM) [8] regulate fatty acid 
metabolism in primary mouse hepatocytes through AMPK-mediated P-ACC. P-ACC is 
considered the best measure of AMPK activation in cells and tissues as it accounts for both 
allosteric and covalent modification components of AMPK activation [23]. In the present 
study, we show that metformin (Figure 1A) and salicylate (Figure 1B) both dose-
dependently inhibit de novo fatty acid synthesis in mouse primary hepatocytes when 
administered alone (IC50 values of 425 μM and 6.1 mM respectively). When 0.1 mM 
metformin (a concentration observed in the portal vein [24]) was combined with 0.5 mM 
salicylate (a serum concentration achieved following ASA administration [25]), P-ACC was 
increased ~2-fold despite undetectable changes with individual doses (Figure 1C). Low 
doses of metformin (0.1 mM) also enhanced P-ACC when combined with salicylate at 1 or 3 
mM (Figure 1C) and this effect was conserved when using higher concentrations of 
metformin (0.25 mM; Supplementary Figure S1A). As expected [6], the inhibitory effects on 
hepatocyte lipogenesis inversely mirrored the enhanced P-ACC at these combination doses 
(Figure 1D; Supplementary Figure S1B). The Chou–Talalay mathematical model theorem 
for drug synergy revealed a synergistic relationship between the two drugs, as indicated by 
combination Index (CI) values < 1 (Figure 1E; Supplementary Figure S1C).
Fatty acid oxidation was unaltered in the presence of low doses of metformin (0.1 mM) or 
salicylate (0.5 mM) alone or in combination (Figure 1F) and although higher dose salicylate 
(3 mM) increased fat oxidation, no further increase was observed with high dose metformin 
(0.5 mM; Supplementary Figure S1D). This is not unexpected since metformin inhibits 
complex-1 of the respiratory chain [26,27] which is required for the oxidation of fatty acyl-
CoA and is consistent with findings from previous studies in hepatocytes [6,28] and skeletal 
muscle [29].
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In cell-free assays, AMP (generated in hepatocytes by metformin [7]) and salicylate 
increased the activity of purified, non-phosphorylated AMPK α1β1γ1 heterotrimers by 
greater than 60-fold, but only had minor effects on allosteric activation when administered 
alone (Figure 1G; Supplementary Figure S1E). Synergy was eliminated in assays using a 
α1β2γ1 complex, confirming the necessity of the β-subunit isoform for the interaction 
(Supplementary Figure S1F). These data are the first to indicate that metformin and 
salicylate synergistically increase AMPK activity/P-ACC through allosteric mechanisms 
involving AMPK β1 independently of upstream kinases.
Metformin and salicylate synergistically activate AMPK and inhibit lipogenesis in human 
primary hepatocytes
Since AMPK subunit expression profiles differ between mouse and human liver [26], we 
examined the responses to metformin and salicylate in primary human hepatocytes to assess 
the translational potential of our findings. Metformin and salicylate each generated dose-
dependent inhibition of fatty acid synthesis (IC50 values of 616 and 522 μM respectively; 
Figure 2A). Importantly, equimolar doses of metformin and salicylate in human hepatocytes 
further reduced the IC50 for fatty acid synthesis to 296 μM (Figure 2A). As observed in 
mouse primary hepatocytes, metformin and salicylate also generated parallel synergistic 
increases in AMPK activation/P-ACC (Figure 2B) and suppression of lipogenesis (Figure 
2C).
Liver lipids are synergistically reduced in high fat diet-fed mice treated with low-dose 
metformin and salsalate
To evaluate whether synergistic effects are also observed in vivo, mice were fed a diet 
containing 60 % kcal from fat (HFD) for 5 weeks followed by 5 weeks of HFD containing 
no drug, 2.5 g/kg metformin, 1 g/kg salsalate or 2.5 g/kg metformin plus 1 g/kg salsalate. 
These doses of metformin and salsalate were chosen based on pilot experiments that 
generated low systemic venous blood levels of metformin (~8–40 μM; Supplementary 
Figure S2A) and salicylate (~150–300 μM; Supplementary Figure S2B) and closely mimic 
those achieved by dosing in humans [i.e. comparable to ~0.5–1.5 g/day metformin [9,30,31], 
ASA (~1 g/day) or salsalate (~0.75 g/day); 25,32,33]. Consistent with our findings in 
cultured hepatocytes, liver P-ACC was enhanced in mice receiving metformin–salsalate 
therapy (Figure 3A). Chronic treatment did not affect weight gain (Figure 3B) or adiposity 
(Figure 3C), a finding consistent with data from metabolic cages indicating that food intake 
(Supplementary Figure S2C) and energy expenditure (Supplementary Figure S2D) were 
unaltered. Despite comparable degrees of adiposity, metformin + salsalate treated mice 
displayed lower RER values (Figure 3D) (which can indicate reduced rates of whole-body 
de novo fatty acid synthesis [34]) and a strong tendency for reduced liver lipid (H & E 
staining; Figure 3E and liver glycerol; Figure 3F).
Insulin sensitivity is enhanced in high fat diet-fed mice treated with metformin and 
salsalsate
Metformin + salsalate treatment improved glucose (Figure 4A) and insulin tolerance (Figure 
4B) and lowered fasting glucose (Figure 4C) compared with control, metformin or salsalate 
only. Serum insulin also tended to be lowest in mice receiving metformin + salsalate diet 
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(Figure 4D). In hyperinsulinaemic–euglycaemic clamp experiments, all treatments tended to 
increase glucose infusion rates (GIRs; Supplementary Figures S2E and S2F), however 
metformin–salsalate combination therapy had the largest effect on liver insulin sensitivity as 
indicated by reductions in HGP (Figure 4E) and greater suppression of hepatic glucose 
output (Figure 4F) compared with the effects of metformin and salsalate alone. Serum 
glucose (Supplementary Figure S2G) and steady-state serum insulin levels (Supplementary 
Figure S2H) were comparable between groups during the clamp, confirming clamped states 
and insulin equality respectively. There were no effects of treatments on GDR 
(Supplementary Figure S2I) or non-esterified fatty acids (NEFA; Supplementary Figure 
S2J), indicating that peripheral insulin sensitivity (skeletal muscle and adipose tissue) was 
unaltered. Insulin signalling, as assessed by P-Ser473–Akt–Akt and P-Thr308Akt–Akt was 
unaltered in clamped livers of mice from any treatment group (Supplementary Figure S2K).
Metformin and ASA independently reduce proinsulin in humans with dysglycaemia
Human hepatocytes were sensitive to salicylate at concentrations achievable following the 
intake of ASA (Figure 2A) [25]. Therefore we used data collected as part of the previously 
completed ORIGIN trial [33] to explore the metabolic effect of metformin and ASA in 8281 
people with either prediabetes or diabetes (median FPG = 6.9 mmol/l and median HbA1c = 
6.4 %) in whom proinsulin and insulin levels were measured. In large clinical studies (such 
as ORIGIN), fasting pro-insulin levels are considered a reliable indicator of insulin 
resistance in individuals with T2D [12]. After adjusting for covariants, metformin (P < 
0.0001) and ASA (P = 0.025) were both independently associated with a lower proinsulin 
level (Table 1) with combination therapy resulting in further reductions (− 0.1801 ± 0.0331, 
P < 0.0001, n = 3381; Table 1).
DISCUSSION
Elevated levels of de novo fatty acid synthesis contribute to the aetiology of NAFLD and 
insulin resistance [2,6] and are observed in insulin resistant [35], diabetic [36] and obese 
[37] humans under fasting and fed conditions. In addition, recent evidence directly confirms 
the contribution of de novo lipogenesis to fatty liver disease in humans using NMR 
spectroscopy [2], highlighting the importance of targeting this process for therapeutic 
intervention in NAFLD. In agreement with previous reports [6,38–40], we show that 
metformin and salicylate dose-dependently inhibit de novo lipogenesis in primary 
hepatocytes from rodents (Figures 1A and 1B). Whereas the concentration of metformin that 
elicited a 50 % reduction in lipogenesis was comparable between mice and human 
hepatocytes (Figures 1A and 2A), the IC50 for salicylate was an order of magnitude lower in 
the human cells (Figure 2A) and comparable to serum levels achieved following ingestion of 
a regular strength ASA [25], revealing notably greater sensitivity of human primary 
hepatocytes to salicylate. We also demonstrate that priming of mouse and human 
hepatocytes with clinical concentrations of metformin that have no effect on fatty acid 
synthesis on their own, dramatically reduce salicylate-induced inhibition of fatty acid 
synthesis and activate AMPK in primary hepatocytes and in vitro assays. These data provide 
the first evidence that metformin and salicylate synergistically activate AMPK and reduce de 
novo fatty acid synthesis in mouse and human primary hepatocytes at clinically achievable 
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doses. This suggests that low serum levels of salicylate (i.e. closer to those achieved with 
extra strength ASA [25]) may be appropriate for inhibiting fatty acid synthesis, particularly 
in NAFLD where hepatic fatty acid synthesis is enhanced. Future studies are required to 
determine why human hepatocytes have enhanced sensitivity to salicylate-induced inhibition 
of lipogenesis compared with those of mice.
Consistent with the synergistic effects of metformin and salicylate on liver AMPK activation 
and de novo lipogenesis, we found that low doses of metformin and salsalate activate 
AMPK/enhance P-ACC (Figure 3A) and tended to lower TG/NAFLD (Figures 3E and 3F) 
in livers of mice made obese through feeding of a HFD over the effect of either drug alone. 
Furthermore, hyperinsulinaemic–euglycaemic clamp experiments revealed that the most 
profound improvement in insulin sensitivity with combination treatment occurred in the 
liver, as indicated by synergistic inhibition of HGP (Figure 4F) and elevated percentage 
suppression of hepatic glucose output (Figure 4G) in metformin + salsalate treated animals 
over those treated with either drug alone, effects that were also observed in the absence of 
any notable differences in peripheral GDRs (Figure S2I). These findings are consistent with 
previous reports indicating that the liver is the primary target of metformin and salsalate 
[41,42].
We examined the effects of metformin + salsalate treatment in HFD-fed mice since they are 
considered a clinically relevant model of human obesity and insulin resistance; however, it is 
known that feeding of a HFD suppresses liver de novo lipogenesis. Therefore, given that 
metformin–salsalate therapy suppressed de novo lipogenesis and had no effect on fatty acid 
oxidation, this lower starting lipogenic rate may have explained why metformin–salsalate 
combination therapy only had modest effects on liver TG and insulin sensitivity. The 
magnitude of metformin–salsalate effect would be anticipated to be higher in insulin-
resistant mouse models that have high rates of liver de novo lipogenesis, such as leptin 
deficient ob/ob mice or in mice fed a high fructose diet. Future studies investigating this 
possibility are warranted.
The therapeutic potential offered by combining low doses of metformin and salicylate is 
highlighted by the fact that the individual doses of these drugs required to fully activate liver 
AMPK may cause toxicity and/or intolerance [9,43]. Direct pharmaceutical remedies for 
NAFLD are also lacking, with weight loss being the best therapeutic strategy identified thus 
far. Whereas metformin consistently reduces liver fat in mice, small studies in humans 
utilizing the liver biopsy technique have yielded mixed results that suggest the effects of 
metformin alone may be relatively modest. It may be that larger clinical trials are needed to 
offset the large sample variance of the liver biopsy technique to clarify these findings. To the 
best of our knowledge, the role of salicylate-based drugs in regulating liver fat in humans 
has not been tested. Future clinical trials testing the effect of metformin and salicylate-based 
drugs on NAFLD using sensitive/direct methods of measuring liver fat and insulin sensitivity 
(NMR spectroscopy and hyperinsulinaemic–euglycaemic clamps respectively) are 
warranted.
In conclusion, the present study is the first to investigate the potential synergy of two widely 
used and well-tolerated drugs, metformin and salicylate, on AMPK activity, liver fatty acid 
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synthesis and insulin resistance. The therapeutic potential of the findings are highlighted by 
our observations showing that metformin combined with salicylate-based therapies (at serum 
concentrations achieved following the intake of an extra strength ASA) lower fatty acid 
synthesis in primary human hepatocytes and lower proinsulin levels in a large clinical cohort 
with dysglycaemia. These data support the use of salicylate-based drugs and metformin in 
combination to maximize activation of liver AMPK and suppress fatty acid synthesis. As 
elevated liver fatty acid synthesis is commonly observed in individuals with NAFLD and 
insulin resistance, combination therapy with salsalate and metformin may be effective for 
treating these prevalent conditions.
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AMPK AMP-activated protein kinase
ASA aspirin
BMI body mass index
CI combination Index
Con control
FPG fasting plasma glucose
GDR glucose disposal rate
GTT glucose tolerance test
H & E haematoxylin and eosin
HbA1c glycated haemoglobin A1c
HFD high fat diet
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HGP hepatic glucose production
ITT insulin tolerance test
Met metformin
NAFLD non-alcoholic fatty liver disease
ORIGIN Outcome Reduction with an Initial Glargine Intervention
P-ACC phosphorylation on acetyl-CoA carboxylase at Ser79/212
PKB protein kinase B
RER respiratory exchange ratio
Sal salicylate
SS salsalate
T2D type 2 diabetes
TG triglycerides
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Figure 1. Metformin and salicylate synergistically activate AMPK and inhibit lipogenesis in 
primary mouse hepatocytes
Dose-dependent inhibition of de novo lipogenesis by (A) Met and (B) salicylate in mouse 
hepatocytes. (C) Ser79/212 P-ACC as a downstream target and marker of AMPK activation in 
primary mouse hepatocytes treated with no drug (Con), Met, salicylate (Sal) or Met + 
salicylate. (D) Inverse suppression of lipogenesis in mouse hepatocytes using the drug 
concentrations in (C). (E) CI compared with fractional effect inhibition (Fa) of lipogenesis 
in mouse hepatocytes treated with Met + salicylate (concentration ratio of 1:10 Met–
salicylate) where CI > 1 indicates an antagonistic, CI = 1 additive or CI < 1 synergistic 
inhibition. Results represent at least two independent experiments performed in triplicate. 
(F) Fatty acid oxidation in mouse hepatocytes treated with no drug, low dose Met (0.1 mM), 
salicylate (0.5 mM) or both. Results from two independent experiments performed in 
triplicate. (G) Activation of AMPK by salicylate + AMP in vitro using purified, 
dephosphorylated AMPK α1β1γ1. Results were generated from four independent 
experiments. All densitometry is a ratio of phosphorylated to total protein. Data are means ± 
S.E.M. except panel (E), which are −means only. *P < 0.05 compared with Con, ‡ P < 0.05 
compared with both respective Met-only and Sal-only doses.
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Figure 2. Metformin and salicylate synergistically activate AMPK and inhibit lipogenesis in 
primary human hepatocytes
(A) Dose-dependent inhibition of lipogenesis by Met, salicylate (Sal) or equimolar Met + 
salicylate (Met + Sal) in human hepatocytes. (B) Ser79/212 P-ACC as a downstream target 
and marker of AMPK activation in primary human hepatocytes treated with no drug (Con), 
0.1 mM Met, 0.3 mM salicylate or Met + salicylate (0.1 and 0.3 mM respectively). (C) 
Suppression of lipogenesis in human primary hepatocytes treated with the drug conditions in 
(B). Results represent experiments from two donors performed in triplicate. All 
densitometry is a ratio of phosphorylated to total protein. Data are means ± S.E.M. *P < 
0.05 compared with Con, ‡P < 0.05 compared with both respective Met only and Sal only 
doses.
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Figure 3. Metformin–salsalate combination treatment synergistically improves metabolic 
homoeostasis and lowers liver lipids in HFD-fed mice
(A) P-ACC Ser79/212 (marker of AMPK activation; P-ACC) in clamped liver samples of 
C57bl/6 mice fed a 60 % HFD for 5 weeks followed by HFD with no drug (Con), 2.5 g/kg 
Met, 1 g/kg salsalate (SS) or Met and salsalate (Met + SS) for an additional 5 weeks. 
Densitometry is the ratio of phosphorylated to total protein. n = 5–8 mice per group. (B) 
Growth curves for mice on the diets indicated. n = 8 mice per group. (C) Percentage body 
adiposity by CT scan analysis. n = 8 mice per group. (D) Mean RER over a 24-h light–dark 
cycle. n = 4 mice per group. (E) Representative H & E staining of hepatic sections (scale 
bars, 100 μm) illustrate liver lipid deposition and (F) total liver TG assayed as total liver 
glycerol. n = 8–12 mice per group. Legends are conserved across bar graph panels. All data 
are means ± S.E.M. *P < 0.05 compared with Con, ‡P < 0.01 compared with both respective 
Met-only and SS-only doses.
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Figure 4. Met and salsalate synergistically improve liver insulin sensitivity in mice
Intraperitoneal (A) GTT and (B) ITT for C57bl/6 mice fed a 60 % HFD for 5 weeks 
followed by HFD with no drug (Con), 2.5 g/kg Met, 1 g/kg salsalate (SS) or Met and 
salsalate (Met + SS) for an additional 5 weeks. (C) Whole blood glucose and (D) serum 
insulin concentrations following a 12-h fast. (E) HGP and (F) percentage suppression of 
hepatic glucose output during hyperinsulinaemic–euglycaemic clamps. Legends are 
conserved across line or bar graph panels. n = 4–5 mice per group for all measures. All data 
are means ± S.E.M. *P < 0.05 compared with Con, ‡P < 0.01 compared with both respective 
Met and SS only doses, †P < 0.05 compared with respective SS only.
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Table 1
Metformin and ASA independently reduce proinsulin in humans with dysglycaemia
Variable
Model 1 (n = 8281) Model 2 (n = 3381)
Estimate ± S.E.M. P-value Estimate ± S.E.M. P-value
Intercept 0.3941 ± 0.0741 <0.0001 0.5253 ± 0.1166 <0.0001
Plasma insulin 0.4119 ± 0.0104 <0.0001 0.4325 ± 0.0166 <0.0001
FPG 0.0518 ± 0.0059 <0.0001 0.0665 ± 0.0088 <0.0001
HbA1c 0.1112 ± 0.0125 <0.0001 0.0755 ± 0.0194 <0.0001
Met − 0.134 ± 0.023 <0.0001 N.D. N.D.
ASA − 0.049 ± 0.022 0.0247 N.D. N.D.
Met + ASA N.D. N.D. − 0.1801 ± 0.0331 <0.0001
Linear regression analyses of proinsulin levels were adjusted for age, sex, weight, plasma insulin, FPG and HbA1c levels. Analyses of metformin 
(Met) and ASA were adjusted for ASA and Met respectively. N.D., not determined.
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